You are here

New Amphetamine Compound Shows Promise in ADHD Patients

SHP465 improves global functioning

Positive results have been reported from a four-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, forced-dose titration, efficacy, and safety study of SHP465 (triple-bead mixed amphetamine salts, Shire) in 275 adults (18 to 55 years of age) with attention-deficit/hyperactivity disorder (ADHD). SHP465 is an investigational oral stimulant medication being evaluated in the United States as a potential treatment for ADHD.

The study’s primary efficacy analysis showed that SHP465 12.5 mg and 37.5 mg, both administered as a daily morning dose, were superior to placebo with respect to the change from baseline on the clinically administered ADHD Rating Scale total score, with mean differences from placebo at week 4 of –8.1 (P < 0.001) for 12.5 mg and –13.3 (P < 0.001) for 37.5 mg. SHP465 12.5-mg and 37.5-mg doses were also significantly better than placebo on the key secondary efficacy analysis of the Clinical Global Impression–Improvement scale at week 4, with scores of –0.8 (P < 0.001) for 12.5 mg and –1.2 (P < 0.001) for 37.5 mg, suggesting a marked clinical improvement in the patients’ global functioning.

Treatment-emergent adverse events with either dose of SHP465 included decreased appetite, xerostomia, insomnia, headache, anxiety, irritability, and bruxism. Adverse events were generally mild-to-moderate in severity and similar to those with other amphetamine compounds.

Shire plans to file a class 2 resubmission of the new drug application for SHP465 by the end of 2016.

ADHD is a neurodevelopmental disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development and that is inconsistent with the developmental level. An estimated 4.4% of adults have ADHD in the U.S.

The specific etiology of ADHD is unknown. The diagnosis is made using criteria specified in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition, or in the International Classification of Diseases, 10th revision. Only a trained health care professional can evaluate and diagnose ADHD.

Although there is no cure for ADHD, accepted treatments have been demonstrated to improve symptoms. Standard treatments include educational approaches and psychological therapies, which may include behavioral modification and/or medication. Ongoing assessment and treatment may be necessary.

Source: Shire; June 29, 2016.

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial